Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study

Gynecol Oncol. 2010 Sep;118(3):283-8. doi: 10.1016/j.ygyno.2010.04.018. Epub 2010 Jun 11.

Abstract

Objective: To evaluate the role of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer (EEC).

Methods: We reviewed 413 patients with EEC from 6 tertiary medical centers between July 1996 and June 2008. All patients were divided into (1) 4 categories of preoperative serum CA-125 levels: <18 U/mL (n=203); 18-35 U/mL (n=114); 36-70 U/mL (n=53); >70 U/mL (n=43) or (2) 3 categories: low-risk (n=240); intermediate-risk (n=99); high-risk diseases (n=74).

Results: Receiver operative curves showed the best cut-off values of 16.2-40.8 U/mL for predicting prognostic factors with 53.4-84.2% of sensitivity, 43.9-81.7% of specificity, 48.8-82.1% of positive predictive value (PPV), 48.5-83.8% of negative predictive value (NPV) and 48.6-83.0% of accuracy. Especially, adnexal involvement was predicted with the highest accuracy (83.0%) at >or=40.8 U/mL. The best cut-off values for preoperative selection of intermediate- to high-risk, and high-risk diseases were 17.3 U/mL and 21.9 U/mL (62.4% and 68.9% of sensitivity; 54.6% and 64.3% of specificity; 57.9% and 64.2% of PPV; 59.2% and 67.4% of NPV, 58.5% and 65.8% of accuracy). Furthermore, >70 U/mL of preoperative serum CA-125 levels was a prognostic factor for poor progression-free and overall survivals.

Conclusions: Serum CA-125 levels may not be useful for predicting most of prognostic factors, and may not contribute to preoperative selection of patients with intermediate- or high-risk disease who need adjuvant radiotherapy in EEC. However, serum CA-125 levels may be helpful in preoperative counseling for young patients who want ovarian preservation, and >70 U/mL could be considered as a risk factor for poor survival.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • CA-125 Antigen / blood*
  • Carcinoma, Endometrioid / blood*
  • Carcinoma, Endometrioid / drug therapy
  • Carcinoma, Endometrioid / radiotherapy
  • Carcinoma, Endometrioid / surgery
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Counseling*
  • Endometrial Neoplasms / blood*
  • Endometrial Neoplasms / drug therapy
  • Endometrial Neoplasms / radiotherapy
  • Endometrial Neoplasms / surgery
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Predictive Value of Tests
  • Preoperative Care
  • Prognosis
  • Radiotherapy, Adjuvant
  • Survival Rate

Substances

  • CA-125 Antigen